Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Finding Study for Depigoid Birch in Allergic Rhinitis
NCT01144429Phase 2Completed
- Sponsor
- LETI Pharma
- Start
- Jun 2010
- Primary completion
- Feb 2011
- Modality
- Recombinant Proteins and Enzymes, Peptide-based Cancer Vaccines, Allergy Immunotherapy
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of depigoid birch in allergic rhinitis (AR) and Rhinoconjunctivitis (RC) (4 arms), sponsored by LETI Pharma. Primary endpoint: Conjunctival Provocation Test Threshold at 22 weeks. Started Jun 2010; status: completed.
02
Drugs
depigoid birch
03
Conditions
allergic rhinitis (AR)Rhinoconjunctivitis (RC)
Beyond the preview
Go deeper on NCT01144429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01144429.